# ImmerseRx mNSCLC Immunotherapy — Augmented reality in mNSCLC

> Augmented reality learning tool for mNSCLC tumor immune evasion and immunotherapy. (iPhone/iPad app by Deborah Wood Associates, Inc.)

- Source: https://appshunter.io/ios/app/immerserx-mnsclc-immunotherapy/id1640327940 (this page in markdown: same URL + `.md`)
- Developer: [Deborah Wood Associates, Inc](https://appshunter.io/developer/506239042)
- Category: Medical, Education
- Price: Free
- Rating: 5.00/5 from 1 App Store ratings
- Age rating: 17+
- Requires: iOS 12.0 · 198 MB
- Languages: American English
- Released: 2022-11-09
- Data updated: 2026-06-13
- Monetization: free
- User reviews in markdown: https://appshunter.io/ios/app/immerserx-mnsclc-immunotherapy/id1640327940/reviews.md

## What is ImmerseRx mNSCLC Immunotherapy?

Powered by Forefront Collaborative, ImmerseRx mNSCLC Immunotherapy is an interactive learning tool that explores tumor immune evasion pathways in metastatic non-small cell lung cancer (mNSCLC), such as the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, and how immunotherapy targets these pathways to lead to tumor cell death. Moving through four interactive scenes, users will also learn about biomarker testing that is necessary to inform treatment decisions around immunotherapy for mNSCLC.

Pinch in and zoom out to scale, rotate, raise, or lower the models; and walk around the 3D objects to view animations up close. This app was created for medical oncologists, oncology nurse practitioners and physician assistants, pulmonologists, pathologists, and other healthcare professionals who are involved in the care of patients with mNSCLC.

This app is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Note: after the creation of this app, additional immunotherapy combinations were approved as first-line treatment options for mNSCLC: cemiplimab plus platinum-based chemotherapy and tremelimumab plus durvalumab plus platinum-based chemotherapy.

## Key features

- Augmented reality exploration
- 3D tumor immune evasion models
- Interactive animations
- Biomarker testing education
- Tumor cell death pathways


## Frequently asked questions about ImmerseRx mNSCLC Immunotherapy

### What is ImmerseRx mNSCLC Immunotherapy?

ImmerseRx mNSCLC Immunotherapy is an augmented reality learning tool designed to educate medical professionals on tumor immune evasion pathways in metastatic non-small cell lung cancer (mNSCLC) and how immunotherapy targets these pathways.

### Who is ImmerseRx mNSCLC Immunotherapy for?

This app is created for medical oncologists, oncology nurse practitioners and physician assistants, pulmonologists, pathologists, and other healthcare professionals involved in the care of patients with mNSCLC.

### What medical topics does ImmerseRx mNSCLC Immunotherapy cover?

It explores tumor immune evasion pathways in mNSCLC, such as the PD-1/PD-L1 pathway, how immunotherapy leads to tumor cell death, and the importance of biomarker testing for treatment decisions.

### How can I interact with the 3D models in ImmerseRx mNSCLC Immunotherapy?

Users can pinch to zoom, scale, rotate, raise, or lower the 3D models. You can also walk around the objects to view animations up close for a comprehensive understanding.

### Is ImmerseRx mNSCLC Immunotherapy free to use?

Yes, ImmerseRx mNSCLC Immunotherapy is available for free. It was supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

### What devices does ImmerseRx mNSCLC Immunotherapy support?

The app is supported on iPhone, iPad, and iPod devices, indicating compatibility across Apple's mobile ecosystem.

### When was ImmerseRx mNSCLC Immunotherapy last updated?

The app was last updated on December 13, 2022, with version 1.0.1. This suggests it is a relatively new application.

### Does ImmerseRx mNSCLC Immunotherapy include information on recent treatment approvals?

While the app explores key pathways, it notes that additional immunotherapy combinations were approved after its creation, such as cemiplimab plus chemotherapy and tremelimumab plus durvalumab plus chemotherapy.

## Version history (last 2 releases)

### 1.0.1 — 2022-12-13

App Store listing updates.

### 1.0 — 2022-11-09

No release notes.

## Apps similar to ImmerseRx mNSCLC Immunotherapy

| App | Rating | Price | Category |
| --- | --- | --- | --- |
| [Manual of Clinical Oncology](https://appshunter.io/ios/app/manual-of-clinical-oncology/id883379133) | 4.5 (18) | Free | Medical |
| [shiftMD](https://appshunter.io/ios/app/shiftmd/id1542637351) | 5.0 (61) | Free | Medical |
| [Anti-VEGF’s in DR, AMD & RVO](https://appshunter.io/ios/app/anti-vegfs-in-dr-amd-and-rvo/id1572324394) | 5.0 (1) | Free | Medical |
| [ASH Pocket Guides](https://appshunter.io/ios/app/ash-pocket-guides/id1055482799) | 3.4 (8) | Free | Medical |
| [OncoAir](https://appshunter.io/ios/app/oncoair/id1527805825) | 5.0 (1) | Free | Medical |
| [CCO Decision Support](https://appshunter.io/ios/app/cco-decision-support/id1489371421) | 4.7 (60) | Free | Medical |

## More apps by Deborah Wood Associates, Inc

- [ImmerseRx: Headache](https://appshunter.io/ios/app/immerserx-headache/id1539046355)
- [ImmerseRx: Psoriatic Arthritis](https://appshunter.io/ios/app/immerserx-psoriatic-arthritis/id1542712960)
- [ImmerseRx: Live Spectator](https://appshunter.io/ios/app/immerserx-live-spectator/id1543006329)

All apps by Deborah Wood Associates, Inc: https://appshunter.io/developer/506239042

---

*Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-06-13.*